Literature DB >> 12612084

Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs.

Bin He1, Elizabeth M Wilson.   

Abstract

Coactivator recruitment by activation function 2 (AF2) in the steroid receptor ligand binding domain takes place through binding of an LXXLL amphipathic alpha-helical motif at the AF2 hydrophobic surface. The androgen receptor (AR) and certain AR coregulators are distinguished by an FXXLF motif that interacts selectively with the AR AF2 site. Here we show that LXXLL and FXXLF motif interactions with steroid receptors are modulated by oppositely charged residues flanking the motifs and charge clusters bordering AF2 in the ligand binding domain. An increased number of charged residues flanking AF2 in the ligand binding domain complement the two previously characterized charge clamp residues in coactivator recruitment. The data suggest a model whereby coactivator recruitment to the receptor AF2 surface is initiated by complementary charge interactions that reflect a reversal of the acidic activation domain-coactivator interaction model.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12612084      PMCID: PMC149467          DOI: 10.1128/MCB.23.6.2135-2150.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  64 in total

1.  Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations.

Authors:  P M Matias; P Donner; R Coelho; M Thomaz; C Peixoto; S Macedo; N Otto; S Joschko; P Scholz; A Wegg; S Bäsler; M Schäfer; U Egner; M A Carrondo
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

2.  Androgen-induced NH2- and COOH-terminal Interaction Inhibits p160 coactivator recruitment by activation function 2.

Authors:  B He; N T Bowen; J T Minges; E M Wilson
Journal:  J Biol Chem       Date:  2001-09-10       Impact factor: 5.157

3.  Distinct classes of transcriptional activating domains function by different mechanisms.

Authors:  D Tasset; L Tora; C Fromental; E Scheer; P Chambon
Journal:  Cell       Date:  1990-09-21       Impact factor: 41.582

4.  Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone.

Authors:  J S Sack; K F Kish; C Wang; R M Attar; S E Kiefer; Y An; G Y Wu; J E Scheffler; M E Salvati; S R Krystek; R Weinmann; H M Einspahr
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

5.  Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors.

Authors:  H E Xu; M H Lambert; V G Montana; K D Plunket; L B Moore; J L Collins; J A Oplinger; S A Kliewer; R T Gampe; D D McKee; J T Moore; T M Willson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

6.  How transcriptional activators bind target proteins.

Authors:  S Hermann; K D Berndt; A P Wright
Journal:  J Biol Chem       Date:  2001-08-20       Impact factor: 5.157

7.  Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors.

Authors:  D M Heery; S Hoare; S Hussain; M G Parker; H Sheppard
Journal:  J Biol Chem       Date:  2000-11-14       Impact factor: 5.157

8.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.

Authors:  C W Gregory; B He; R T Johnson; O H Ford; J L Mohler; F S French; E M Wilson
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

9.  Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation.

Authors:  E M McInerney; D W Rose; S E Flynn; S Westin; T M Mullen; A Krones; J Inostroza; J Torchia; R T Nolte; N Assa-Munt; M V Milburn; C K Glass; M G Rosenfeld
Journal:  Genes Dev       Date:  1998-11-01       Impact factor: 11.361

10.  The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.

Authors:  A K Shiau; D Barstad; P M Loria; L Cheng; P J Kushner; D A Agard; G L Greene
Journal:  Cell       Date:  1998-12-23       Impact factor: 41.582

View more
  35 in total

1.  CCAAT/Enhancer-binding protein beta DNA binding is auto-inhibited by multiple elements that also mediate association with p300/CREB-binding protein (CBP).

Authors:  Sook Lee; Maria Miller; Jon D Shuman; Peter F Johnson
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

2.  Thermodynamic characterization of the interaction between CAR-RXR and SRC-1 peptide by isothermal titration calorimetry.

Authors:  Edward Wright; Jeremy Vincent; Elias J Fernandez
Journal:  Biochemistry       Date:  2007-01-23       Impact factor: 3.162

3.  Perspectives on mechanisms of gene regulation by 1,25-dihydroxyvitamin D3 and its receptor.

Authors:  J Wesley Pike; Mark B Meyer; Makoto Watanuki; Sungtae Kim; Lee A Zella; Jackie A Fretz; Miwa Yamazaki; Nirupama K Shevde
Journal:  J Steroid Biochem Mol Biol       Date:  2007-01-12       Impact factor: 4.292

4.  Androgen receptor regulation by histone methyltransferase Suppressor of variegation 3-9 homolog 2 and Melanoma antigen-A11.

Authors:  Emily B Askew; Suxia Bai; Amanda B Parris; John T Minges; Elizabeth M Wilson
Journal:  Mol Cell Endocrinol       Date:  2016-12-29       Impact factor: 4.102

5.  Gain in transcriptional activity by primate-specific coevolution of melanoma antigen-A11 and its interaction site in androgen receptor.

Authors:  Qiang Liu; Shifeng Su; Amanda J Blackwelder; John T Minges; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

6.  Transcriptional synergy between melanoma antigen gene protein-A11 (MAGE-11) and p300 in androgen receptor signaling.

Authors:  Emily B Askew; Suxia Bai; Amanda J Blackwelder; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2010-05-06       Impact factor: 5.157

7.  Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor.

Authors:  X Edward Zhou; Kelly M Suino-Powell; Jun Li; Yuanzheng He; Jeffrey P Mackeigan; Karsten Melcher; Eu-Leong Yong; H Eric Xu
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

8.  Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor.

Authors:  Myles C Hodgson; Howard C Shen; Anthony N Hollenberg; Steven P Balk
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

9.  Kinetic and thermodynamic characterization of dihydrotestosterone-induced conformational perturbations in androgen receptor ligand-binding domain.

Authors:  Ravi Jasuja; Jagadish Ulloor; Christopher M Yengo; Karen Choong; Andrei Y Istomin; Dennis R Livesay; Donald J Jacobs; Ronald S Swerdloff; Jaroslava Miksovská; Randy W Larsen; Shalender Bhasin
Journal:  Mol Endocrinol       Date:  2009-05-14

10.  A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin.

Authors:  Eleanor F Need; Howard I Scher; Amelia A Peters; Nicole L Moore; Albert Cheong; Charles J Ryan; Gary A Wittert; Villis R Marshall; Wayne D Tilley; Grant Buchanan
Journal:  Endocrinology       Date:  2009-03-12       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.